Pfizer Withheld Crucial Data In Lipitor Patent Filing, Ranbaxy Claims
By Marius Meland ( November 23, 2004, 12:00 AM EST) -- Pfizer Inc. withheld crucial scientific data that might have influenced the patent review board's decision to grant the drug maker a second patent for Lipitor, attorneys for Indian generics maker Ranbaxy Laboratories Ltd. argued at the opening of the closely watched trial over patent rights to the blockbuster anti-cholesterol drug....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.